Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTB 7550

Next Previous
X
Search
Drug Profile

GTB 7550

Alternative Names: CAM-161519; GTB-7550; GTB-7750 TriKE

Latest Information Update: 15 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer GT Biopharma
  • Class Antibodies; Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic lymphocytic leukaemia; Haematological malignancies

Most Recent Events

  • 10 Jun 2022 Pharmacodynamics data from a preclinical trials in chronic lymphocytic leukaemia and haematological malignancies released by GT Biopharma
  • 01 Jan 2022 Preclinical trials in Chronic lymphocytic leukaemia in USA (Parenteral)
  • 01 Jan 2022 Preclinical trials in Haematological malignancies in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top